Can
dynamic 18F-NaF PET/CT
multiple myeloma
progression-free survival (PFS)
standardized uptake value (SUV)
two-tissue compartment model
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 May 2020
23 May 2020
Historique:
received:
08
04
2020
revised:
11
05
2020
accepted:
21
05
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
28
5
2020
Statut:
epublish
Résumé
There is an unmet need for positron emission tomography (PET) radiotracers that can image bone disease in multiple myeloma (MM) in a more sensitive and specific way than the widely used
Identifiants
pubmed: 32456181
pii: cancers12051335
doi: 10.3390/cancers12051335
pmc: PMC7281312
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Eur J Nucl Med Mol Imaging. 2020 May 19;:
pubmed: 32430580
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1343-53
pubmed: 24562650
Molecules. 2019 Dec 29;25(1):
pubmed: 31905752
Theranostics. 2016 Jan 01;6(2):254-61
pubmed: 26877783
J Nucl Med. 1992 May;33(5):633-42
pubmed: 1569473
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):50-62
pubmed: 27573638
Am J Nucl Med Mol Imaging. 2017 Sep 01;7(4):148-156
pubmed: 28913153
Anticancer Res. 2019 Apr;39(4):1943-1952
pubmed: 30952737
Leuk Lymphoma. 2016 May;57(5):1114-21
pubmed: 26690712
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
J Nucl Med. 2010 Nov;51(11):1813-20
pubmed: 21051652
Blood. 2011 Dec 1;118(23):5989-95
pubmed: 21900189
Best Pract Res Clin Haematol. 2007 Dec;20(4):613-24
pubmed: 18070709
Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1767-1777
pubmed: 26201825
J Nucl Med. 2010 Dec;51(12):1826-9
pubmed: 21078790
Cancer Imaging. 2012 Sep 28;12:283-9
pubmed: 23033440
Eur J Nucl Med Mol Imaging. 2020 Apr 3;:
pubmed: 32246208
Blood. 2012 Jan 26;119(4):940-8
pubmed: 22160383
Blood Cancer J. 2017 Oct 6;7(10):e615
pubmed: 28984867
Blood. 2017 Jul 6;130(1):30-34
pubmed: 28432222
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Oncologist. 2020 Feb;25(2):112-118
pubmed: 32043788
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
J Nucl Med. 1991 Jul;32(7):1432-8
pubmed: 2066802
Br J Haematol. 2012 Dec;159(5):499-513
pubmed: 22881361
EMBO Mol Med. 2015 Mar 03;7(4):477-87
pubmed: 25736399
Med Inform (Lond). 1998 Jul-Sep;23(3):207-14
pubmed: 9785322
Blood. 2009 Sep 3;114(10):2068-76
pubmed: 19443657
Theranostics. 2017 Apr 8;7(6):1589-1597
pubmed: 28529638
Ann Oncol. 2010 Feb;21(2):325-30
pubmed: 19633044
Br J Haematol. 2018 Jun;181(5):701-703
pubmed: 28466502
Theranostics. 2017 Jul 23;7(11):2956-2964
pubmed: 28824728
Ann Nucl Med. 2013 Jan;27(1):78-83
pubmed: 22914967
Cancer. 2012 Apr 15;118(8):1971-81
pubmed: 21887677
J Nucl Med. 2008 Jan;49(1):68-78
pubmed: 18077529
J Nucl Med. 2015 Feb;56(2):222-8
pubmed: 25593113
Haematologica. 2019 Sep;104(9):e420-e423
pubmed: 30765474
J Nucl Med. 1997 Nov;38(11):1818-23
pubmed: 9374364
AJR Am J Roentgenol. 2010 Nov;195(5):1057-65
pubmed: 20966307
Clin Nucl Med. 2015 Jun;40(6):e300-7
pubmed: 25783508
Phys Med Biol. 2017 May 7;62(9):3566-3581
pubmed: 28379842
Lancet Oncol. 2017 Apr;18(4):e206-e217
pubmed: 28368259
J Nucl Med. 2020 Feb;61(2):285-291
pubmed: 31302637
Hematol Oncol. 2019 Apr;37(2):193-201
pubmed: 30821017
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):537-546
pubmed: 31776631
Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719
pubmed: 29270787
Ann Hematol. 2015 Sep;94(9):1567-75
pubmed: 26068066